Phase II trial of cisplatin (CPDD) in previously treated patients with advanced soft tissue sarcoma
- 15 November 1982
- Vol. 50 (10) , 2031-2033
- https://doi.org/10.1002/1097-0142(19821115)50:10<2031::aid-cncr2820501010>3.0.co;2-z
Abstract
Thirty-six previously treated adult patients with advanced soft tissue sarcomas received CPDD 120 mg/m2 with mannitol diuresis. There were only two (6%) partial responses and five (15%) minor responses in 34 evaluable patients. Toxicity included nausea and vomiting, myelosuppression, mild ototoxicity and mild to moderate, transient nephrotoxicity. CPDD has minimal antitumor activity in previously treated patients with soft tissue sarcomas.This publication has 3 references indexed in Scilit:
- E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcomaPublished by Elsevier ,1979
- High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresisCancer, 1977
- Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamideCancer, 1972